Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sleep drug shows promise for narcolepsy patients

NCT ID NCT06792708

Symptom relief Sponsor: Avadel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 71 adults with narcolepsy who started taking LUMRYZ, a medication for excessive daytime sleepiness. Over 4 months, participants filled out questionnaires about their symptoms, how they felt about the drug, and their quality of life. The goal was to see if LUMRYZ helps reduce sleepiness in real-world settings, not to find a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

71 people

The number who actually took part.

Started

Jul 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults (18 years and older) with a diagnosis of Type 1 or Type 2 narcolepsy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults with narcolepsy * Oxybate naive or prior treatment with twice-nightly oxybate * Access to smart phone, tablet or laptop with reliable internet connection * Able to read/understand English * Written informed consent and ability to comply with schedule Exclusion Criteria: * Already using LUMRYZ * Clinical or mental health condition excluded by LUMRYZ label * Any other condition/situation that would adversely impact participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Narcolepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Narcolepsy

Contacts and locations

Locations

  • Abington Neurological Associates

    Abington, Pennsylvania, 19001, United States

  • Bogan Sleep Consultants

    Columbia, South Carolina, 29201, United States

  • Comprehensive Sleep Center

    East Lansing, Michigan, 48823, United States

  • Ghaly Sleep Management Services

    East Syracuse, New York, 13057, United States

  • Jeremy D McConnell, MD PA

    Bradenton, Florida, 34209, United States

  • Northwest Houston Neurology

    Tomball, Texas, 77375, United States

  • Ohio Sleep Medicine Institute

    Dublin, Ohio, 43017, United States

  • Patient First MD

    Middletown, New Jersey, 07748, United States

  • Pulmonology Associates, Inc.

    Wynnewood, Pennsylvania, 19096, United States

  • Respiratory Specialists

    Wyomissing, Pennsylvania, 19610, United States

  • Tricoastal Narcolepsy and Sleep Disorder Center

    Sugar Land, Texas, 77478, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.